Bristol Myers touts PhIII Opdivo win in urothelial carcinoma; Liminal BioSciences goes private
Bristol Myers Squibb said Tuesday that a sub-study of a Phase III trial testing Opdivo with cisplatin-based chemotherapy, followed by Opdivo monotherapy, met the primary endpoints of overall survival and progression-free survival.
The sub-study was in patients with unresectable or metastatic urothelial carcinoma as a first-line treatment, randomizing 608 patients to either receive Opdivo with chemo every three weeks or chemotherapy only. Efficacy measures were met, and the company added that the combination had a “tolerable safety profile.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
